Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573291 | 0.90 | HTR1A (0.40) | HTR1ASLC6A4HTR2AHTR2CPDE4A | |
| SCHEMBL3557633 | 0.73 | HTR1A (0.49) | HTR1ASLC6A4HTR2AHTR2CPDE4A | |
| SCHEMBL3558267 | 0.71 | HTR1A (0.74) | HTR1A | |
| SCHEMBL4968271 | 0.71 | HTR1A (0.47) | HTR1ASLC6A4MAPT | |
| SCHEMBL3558251 | 0.67 | HTR1A (0.72) | HTR1ASLC6A4 | |
| SCHEMBL3561450 | 0.67 | SLC6A4 (0.68) | HTR1ASLC6A4HTR2AHTR2CMAPT | |
| SCHEMBL3558233 | 0.66 | HTR1A (0.70) | HTR1ASLC6A4 | |
| SCHEMBL3573288 | 0.66 | HTR1A (0.41) | HTR1ASLC6A4HTR2AHTR2CPDE4A | |
| SCHEMBL3560019 | 0.65 | HTR1A (0.77) | HTR1A | |
| SCHEMBL3559423 | 0.65 | HTR1A (0.70) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | claimed |
| US-20080226714-A1 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-09-18 | — | — | US | claimed |
| US-20080199518-A1 | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution | WYETH (US) | 2008-08-21 | — | — | US | claimed |
| WO-2008101139-A1 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2008067399-A2 | CONTROLLED-RELEASE MULTI-LAYER FORMULATION OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-TH1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-06-05 | — | — | WO | claimed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | claimed |
| US-7671056-B2 | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-2035384-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080226714-A1 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080199518-A1 | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution | WYETH (US) | 2008-08-21 | — | — | US | disclosed |
| WO-2008101139-A1 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008067399-A2 | CONTROLLED-RELEASE MULTI-LAYER FORMULATION OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-TH1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | WYETH (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | WYETH | 2008-03-06 | — | — | US | disclosed |
| EP-1888559-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | Wyeth a Corporation of the State of Delaware (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007146072-A2 | PROCESS FOR SYNTHESIZING PIPERAZINE-PIPERIDINE COMPOUNDS | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| WO-2006135839-A2 | PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR | WYETH (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058523-A1 | Processes for synthesizing piperazine-piperidine compounds | HTR5A, HTR2A, HTR1A | HTR1A 3/4885SLC6A4 64/4885HTR2A 2/4885 |
| US-20080226714-A1 | SUSTAINED-RELEASE TABLET FORMULATIONS OF PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR HAVING ENHANCED INTESTINAL DISSOLUTION | HTR5A, HTR2A, HTR1A | HTR1A 3/4885SLC6A4 58/4885HTR2A 2/4885 |
| US-20070027160-A1 | 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction | HTR5A, HTR2C, HTR1D | HTR1A 4/4885SLC6A4 56/4885HTR2A 6/4885 |
| US-20080199518-A1 | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution | HTR5A, HTR2C, HTR2A | HTR1A 5/4885SLC6A4 88/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.